Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deals of the Week: Sanofi/Selecta, Evotec/Probiodrug, Nestle/Chi-Med…

Executive Summary

European economists meeting in London discuss drug innovation’s costs to the larger health system, research funding sources, and “sin taxes.”

You may also be interested in...



Curis Propels Two Proprietary Drugs Forward In Plan To Retain Value

Cancer drug developer Curis held its first R&D day Oct. 3, a sign its early pipeline is maturing. The company outlined development plans for two proprietary drugs, an IAP inhibitor and a PI3K/HDAC inhibitor, both in early clinical development. As for partnering those assets, CEO Passeri said the company is looking to retain more value for them than it did for Erivedge.

Sanofi And Selecta To Partner On Immunotherapies For Life-Threatening Allergies

Vaccine and immunotherapy-focused Selecta, up to now focused on grants for funding, signs its first big pharma partner around targeted, antigen-specific programs for undisclosed allergies.

AstraZeneca Goes Virtual In Neuroscience R&D As Part Of Workforce Reduction

AstraZeneca is to slash 12% of its workforce in the next three years, as the company forecasts declining revenues in 2012 because of its steep patent cliff, government pricing interventions and R&D pipeline failures.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

OM013164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel